P1 - Poster Session I

Event Time: Sunday April 23, 2017 8:30 am to 5:30 pm
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Epilepsy/Clinical Neurophysiology (EEG), General Neurology, Headache, Infectious Disease, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-oncology, Pain and Palliative Care, Practice, Policy, and Ethics, Research Methodology, Education, and History
Director(s):
Description: A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 4:00 pm to 5:30 pm.
Completion Message:
CME Credits: 0
Core Competencies:

Abstract Presenters

Parkinson's Disease: Biomarkers and Genetics
Start Time Pub. Title Presenter
4:00 PM 001 Genome-wide Association for the Park10 Locus in Iopathic, Autopsy-proven, Lewy Body Parkinson Disease and Autopsy-Proven Controls Jeffery Vance, MD, PhD
Disclosure:
Dr. Vance has nothing to disclose.

4:00 PM 002 Genetic analysis of the Glucocerebrosidase gene in Indian patients with Parkinson’s disease Ravi Yadav, MD, DM
Disclosure:
Dr. Yadav has nothing to disclose.

4:00 PM 003 Interplay Between LRRK2 Action in Neurons and Macrophages in Mediating ?-Synuclein linked Neurodegeneration Hisham Abdelmotilib
Disclosure:
Dr. Abdelmotilib has nothing to disclose.

4:00 PM 004 Proteome-scale Molecular Networks Mechanistically Link Alpha-synuclein to Diverse Genetic Risk Factors for Parkinsonism Vikram Khurana, MD, PhD
Disclosure:
Dr. Khurana has received personal compensation for activities with Yumanity Therapeutics as an employee. Dr. Khurana holds stock and/or stock options in Yumanity Therapeutics.

4:00 PM 005 Baseline Cerebrospinal Fluid Biomarkers Associated with Longitudinal Cognitive and Functional Decline in Early Parkinson′s Disease Olga Kofman
Disclosure:
Dr. Kofman has nothing to disclose.

4:00 PM 006 Elevated GM3 Plasma Concentration in Parkinson’s Disease: a Lipidomics Analysis Roy Alcalay, MD
Disclosure:
Dr. Alcalay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Denali, Prophase, and Genzyme Sanofi.

4:00 PM 007 Environmental Risk Factors and Plasma-Based miRNA Levels in Parkinson’s disease Patients Dominic Facciponte, Other
Disclosure:
Dr. Facciponte has nothing to disclose.

4:00 PM 008 Functional MAOB gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson’s disease Matthias Löhle
Disclosure:
Dr. Lohle has received personal compensation for activities with UCB Pharma and AbbVie for speaking and serving on a scientific advisory board.

4:00 PM 009 Serum Oxidant and Antioxidant Status of Patients with Parkinson’s Disease Mustafa Yurtdas
Disclosure:
Dr. YURTDAS has nothing to disclose.

4:00 PM 010 Enteric neurons reveal substantial ex vivo mitochondrial changes in Parkinson’s disease Paul Antony
Disclosure:
Dr. Antony has nothing to disclose.

4:00 PM 011 An Exploratory Study of Associations Between longitudinal Changes of different CSF Biomarkers in Early, Drug-naiive Parkinson's Disease Patients Mahsa Dolatshahi
Disclosure:
Dr. Dolatshahi has nothing to disclose.

4:00 PM 012 Lewy Body and Tau pathology in a patient with parkinsonism, cognitive decline, rapid progression and the GBA1 T369M variant Hannah Walters, MD
Disclosure:
Dr. Walters has nothing to disclose.

4:00 PM 013 Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) Carly Linder
Disclosure:
Dr. Linder has nothing to disclose.

4:00 PM 014 Comparison of quantitative measures of Pupil Light Reflex measured using Automated Pupillometer in patients with Parkinson’s disease and controls Robin Ulep
Disclosure:
Dr. Ulep has nothing to disclose.

4:00 PM 015 Neurons with oscillatory activity in the basal ganglia and the ventral thalamus in patients with Parkinson’s disease Ping Zhuang, PhD
Disclosure:
Dr. Zhuang has nothing to disclose.

4:00 PM 016 Objective gait parameters as a noninvasive biomarker for freezing of gait in Parkinson disease Jesal Shah
Disclosure:
Dr. Shah has nothing to disclose.

Parkinson's Disease: Therapeutics and Telehealth I
Start Time Pub. Title Presenter
4:00 PM 017 Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase Robert A. Hauser, MD, MBA, FAAN
Disclosure:
Dr. Hauser has nothing to disclose.

4:00 PM 018 Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Christopher Goetz, MD, FAAN
Disclosure:
Dr. Goetz has nothing to disclose.

4:00 PM 019 Identification of the Carbidopa Concentration in Subcutaneously Administered ND0612 (Levodopa/Carbidopa) that Provides Optimal Levodopa Bioavailability Liat Adar
Disclosure:
L. Adar has received personal compensation for activities with NeuroDerm Ltd. as an employee.

4:00 PM 020 Duration of “on” periods after treatment with extended-release vs. immediate-release carbidopa-levodopa in patients with advanced Parkinson’s disease William Ondo, MD
Disclosure:
Dr. Ondo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Lundbeck, UCB, US WorldMeds, Acadia. Dr. Ondo has received research support from dbeck, Tremor Research Group, Dystonia Coalition, Restless Leg Syndrome Foundation, Acorda.

4:00 PM 021 Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of PD Home Diary Results Caroline Tanner, MD, PhD, FAAN
Disclosure:
Dr. Tanner has nothing to disclose.

4:00 PM 022 Rotigotine transdermal patch attenuates freezing of gait during wearing off in patients with Parkinson’s disease Ken Ikeda, MD, PhD
Disclosure:
Dr. Ikeda has nothing to disclose.

4:00 PM 023 Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL-130277) in patient with Parkinson’s disease Hubert Fernandez, MD, FAAN
Disclosure:
Dr. Fernandez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prime Education, Inc., International Parkinson and Movement Disorders Society, Carling Communications, Medscape, AbbVie, Biogen, GE Health Care, Inventiv, Kyowa Hakko Kirin, Lundbeck, Merz Pharmaceuticals, Voyager, Sunovion, and Pfizer. Dr. Fernandez has received personal compensation in an editorial capacity for International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site. Dr. Fernandez has received research support from AbbVie, Acadia, Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, and Synosia.

4:00 PM 024 Effect of levodopa-carbidopa intestinal gel on dyskinesia: design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients Angelo Antonini, MD
Disclosure:
Dr. Antonini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Boston Scientific, Boheringer Ingelheim, AbbVie Inc., Zambon. Dr. Antonini has received research support from Mundipharma.

4:00 PM 025 ND0612 – a Newly Developed Liquid Levodopa/Carbidopa Formulation Administered Continuously Subcutaneously by a Mini-pump – Patient Use Perspective Sophie Nash
Disclosure:
An employee of NeuroDerm Ltd..

4:00 PM 026 Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis Ahmed Negida
Disclosure:
Dr. Abdou Negida has nothing to disclose.

4:00 PM 027 Dosing and efficacy of extended-release carbidopa-levodopa in advanced Parkinson’s disease patients with or without concomitant medication use Suneel Gupta, PhD
Disclosure:
Employee of Impax Laboratories, Inc.; Holds stock in Impax Laboratories, Inc..

4:00 PM 028 Effects of age and disease duration on quality of life outcomes in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusions: a post-hoc analysis from the GLORIA registry Angelo Antonini
Disclosure:
Dr. Antonini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Boston Scientific, Boheringer Ingelheim, AbbVie Inc., Zambon. Dr. Antonini has received research support from Mundipharma.

4:00 PM 029 Clinical Experience with Outpatient Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients in the Medication ON State Phaedra Dowell, MD
Disclosure:
Dr. Dowell has nothing to disclose.

4:00 PM 030 Effect of “Off” Time on the Recommended Starting Dose for Rytary Nishit Modi
Disclosure:
Dr. Modi is an employee of Impax Labs.. Dr. Modi is an employee of Impax labs and holds stock options greater than $10,000.. Dr. Modi is an employee of Impax labs..

Graduate Medical Education Research
Start Time Pub. Title Presenter
4:00 PM 031 Recognizing the Deficits in Neurology Residents’ Neurophysiology Knowledge: Results from a National Survey Kate Daniello, MD
Disclosure:
Dr. Daniello has nothing to disclose.

4:00 PM 032 Inter-Provider Communication Using a Scheduled Provider Alert-Response Communication System (SPARCS) in 3 Inpatient Neurology Units James Siegler
Disclosure:
Dr. Siegler has nothing to disclose.

4:00 PM 033 A Teleneurology Curriculum: Applications, Evidence, and Practice for Neurology Residents Nicole Chiota-McCollum, MD
Disclosure:
Dr. Chiota-McCollum has nothing to disclose.

4:00 PM 034 The Accreditation and Certification of the Movement Disorders Subspecialty Sarah O'Shea, MD
Disclosure:
Dr. O'Shea has nothing to disclose.

4:00 PM 035 A Four Part Communication Skills Training Curriculum for Neurology Residents Michael Lyerly, MD
Disclosure:
Dr. Lyerly has nothing to disclose.

4:00 PM 036 Peer observation and feedback of resident teaching during neurology rounds David Lin, MD
Disclosure:
Dr. Lin has nothing to disclose.

4:00 PM 037 Physician Retention in the Same State as Residency Training: Data From 1 Michigan GME Institution Tracy J Koehler
Disclosure:
Dr. Koehler has nothing to disclose.

4:00 PM 038 The Status of Multiple Sclerosis and Neuroimmunology Fellowship Training in the United States: A Pilot Study Ahmed Z Obeidat, MD, PhD
Disclosure:
Dr. Obeidat has nothing to disclose.

4:00 PM 039 Feasibility of Google Glass for Remote Resident Supervision and Evaluation Joseph Carrera, MD
Disclosure:
Dr. Carrera has nothing to disclose.

4:00 PM 040 Early Career Neurologists′ Feedback About the Primary Care and Psychiatry Components of Residency Training Laurie Gutmann, MD, FAAN
Disclosure:
Dr. Gutmann has nothing to disclose.

4:00 PM 041 Neurology Training for Psychiatric Residents: A Narrative Review Daniel Shalev
Disclosure:
Dr. Shalev has nothing to disclose.

4:00 PM 042 Intensive Training can lead to significant improvement in resident EEG skills Anand Venkatraman, MBBS
Disclosure:
Dr. Venkatraman has nothing to disclose.

4:00 PM 043 Impact of Live Patient Didactic Conference on Neurology Resident Outpatient Education Christopher Doughty, MD
Disclosure:
Dr. Doughty has nothing to disclose.

4:00 PM 044 Impact of epilepsy curriculum redesign and milestone self-assessment in neurology residency Heidi Munger Clary, MD, MPH
Disclosure:
Dr. Munger Clary has nothing to disclose.

4:00 PM 045 Non-Neurologist Self Assessment of Emergency Neurology Proficiency and Interest in a Novel Intensive Stroke and Neurocritical Care Training Program: The X-CHANGE Program Alan Yee, DO
Disclosure:
Dr. Yee has nothing to disclose.

4:00 PM 046 Published Coma Simulation had Face Validity in allowing trainees to demonstrate Neurology Residency Milestones and AAMC Entrustable Professional Activities Diana Barratt, MD,MPH
Disclosure:
Dr. Barratt has nothing to disclose.

4:00 PM 047 Creation of a diversity and inclusion certificate program for neurology residents Anna Bank, MD
Disclosure:
Dr. Bank has nothing to disclose.

4:00 PM 048 Bad News or Life Altering Diagnoses? Neurology Residents' Attitudes towards Disclosing Diagnoses Janis Miyasaki, MD, FAAN
Disclosure:
Dr. Miyasaki has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cynapsus and Synovion, GE. Dr. Miyasaki has received research support from Allergan.

4:00 PM 049 The Child Neurology and Neurodevelopmental Disabilities Trainee-as-Teacher: Tailoring a Clinical Teaching Curriculum to Specialty Trainees’ Needs and Developmental Roles Miya Bernson-Leung
Disclosure:
Dr. Bernson-Leung has nothing to disclose.

4:00 PM 050 The Power of Partnerships: Collaborating to Address Local Caregiver and Patient Needs in National CME Programming Matthew Frese
Disclosure:

4:00 PM 051 Fatigue and sleep deprivation in interns of medicine and its burden in vehicle driving Brian Jose Villafuerte Trisolini
Disclosure:
Dr. Villafuerte Trisolini has nothing to disclose.

Undergraduate Medical Education Research
Start Time Pub. Title Presenter
4:00 PM 052 Numerical vs Narrative: a comparison between methods to measure student clerkship performance Josef Bartels
Disclosure:
Dr. Bartels has nothing to disclose.

4:00 PM 053 An integrated emergency department based neurology curriculum for medical students: design, implementation, and results David Lin
Disclosure:
Dr. Lin has nothing to disclose.

4:00 PM 054 Neurology Clerkship Students’ Perceptions of Assessment for Learning Using Frequent Mini-CEXs Justin Mowchun
Disclosure:
Dr. Mowchun has nothing to disclose.

4:00 PM 055 Precision Education in Neurology: The impact of student learning preference on predicting knowledge, skills, and satisfaction by type of learning environment in neurology Irene Vargas
Disclosure:
Dr. Vargas has nothing to disclose.

4:00 PM 056 Compassionate Neurological Care OSCE-A Primer for Teaching Patient Centered Care in Neurology Clerkship Anukrati Shukla, MBBS
Disclosure:
Dr. Shukla has nothing to disclose.

4:00 PM 057 Brain death determination: Addressing the Concept at the Medical Student Level to Ensure Competency and Consistency in Practice Sheryl Strasser, MD
Disclosure:
Dr. Strasser has nothing to disclose.

4:00 PM 058 Redesigning the Student Interest Group in Neurologu (SIGN) Chapters Amal Al-Lozi
Disclosure:
Dr. Al-Lozi has nothing to disclose.

4:00 PM 059 Simulation-Based Medical Education in Acute Neurologic Emergencies Mustafa Ansari, MD
Disclosure:
Dr. Ansari has nothing to disclose.

4:00 PM 060 Simulation-based training in brain death determination incorporating family discussion: An update on an ongoing project Preston Douglas, MD
Disclosure:
Dr. Douglas has nothing to disclose.

4:00 PM 061 Outcome of a model for medical student engagement in child neurology Katherine Mathews, MD
Disclosure:
Dr. Mathews has nothing to disclose.

4:00 PM 062 Impact of Review Sessions on NBME Subject Examination Performance Suma Das, MD
Disclosure:
Dr. Shah has nothing to disclose.

4:00 PM 063 Moving the Neurology Clerkship to the Third Year: A Survey of Medical Students Michelle Caunca
Disclosure:
Dr. Caunca has nothing to disclose.

4:00 PM 064 Utility of an Emergency Neurologic Life Support- based simulation course for First Year Neurology resident independent call readiness: A Quality Improvement Project Ferhad Bashir, MD
Disclosure:
Dr. Bashir has nothing to disclose.

Practice, Policy, and Ethics I
Start Time Pub. Title Presenter
4:00 PM 065 Resident-driven protocol for improving admissions to the Epilepsy Monitoring Unit Kate Essad, MD
Disclosure:
Dr. Essad has nothing to disclose.

4:00 PM 066 Length of stay for stroke patients to a primary stroke center is dependent on the day of admission Davida Goltz, MD
Disclosure:
Dr. Goltz has nothing to disclose.

4:00 PM 067 Derivation and Validation of a Proposed Long Length of Stay (? 7 days) Score in Patients Hospitalized for Acute Ischemic Stroke Sadiqa Mahmood, BDS
Disclosure:
Dr. Mahmood has nothing to disclose.

4:00 PM 068 Using Root Cause Analysis to Improve Patient Safety in the Outpatient Neurology Setting Ramesh Cherukuri, MD
Disclosure:
Dr. Cherukuri has nothing to disclose.

4:00 PM 069 NA NA NA
Disclosure:

4:00 PM 070 NA NA NA
Disclosure:

Movement Disorders ePoster Session
Start Time Pub. Title Presenter
4:00 PM 071 Evaluation of dynamic gait stability after a single-session of waist-pull perturbation training in Parkinson’s disease using an Active Tethered Pelvic Assist Device (A-TPAD). Lan Luo, MD
Disclosure:
Dr. Luo has nothing to disclose.

4:00 PM 072 Altered small world brain connectivity in patients with Primary Writing Tremor: A graph theory approach Abhishek Lenka
Disclosure:
Dr. Lenka has nothing to disclose.

4:00 PM 073 Whole Genome Sequencing and Rare Variant Analysis in Essential Tremor Families Lorraine Clark, PhD
Disclosure:
Dr. Clark has nothing to disclose.

4:00 PM 074 Steroid-responsive encephalopathy with associated thyroiditis (SREAT) presenting with pure cerebellar ataxia Pichet Termsarasab, MD
Disclosure:
Dr. Termsarasab has nothing to disclose.

4:00 PM 075 Sensory trick phenomenon in cervical dystonia: a functional MRI study Elisabetta Sarasso
Disclosure:
Dr. Sarasso has nothing to disclose.

4:00 PM 076 Advanced Neuromelanin Sensitive MRI Measures Detect Parkinson's Disease Effects in Catecholamine Nuclei: Discovery and Validation in Separate Cohorts Daniel Huddleston, MD
Disclosure:
Dr. Huddleston has nothing to disclose.

4:00 PM 077 Severe Dystonia as a Manifestation of West Nile Neuroinvasive Disease Rachelle Herring, MD
Disclosure:
Dr. Herring has nothing to disclose.

4:00 PM 078 Powassan virus causing Post-encephalitic Parkinsonism Shivam Om Mittal, MD
Disclosure:
Dr. Mittal has nothing to disclose.

4:00 PM 079 Adult Onset Alexander Disease with Novel GFAP p.Ser385Cys Mutation Scott Le, DO
Disclosure:
Dr. Le has nothing to disclose.

4:00 PM 080 Long Term Follow up of Weight Changes in STN and GPi Deep Brain Stimulation Syed Shah, MD
Disclosure:
Dr. Shah has nothing to disclose.

Aging and Dementia: Genetic Studies
Start Time Pub. Title Presenter
4:00 PM 081 Clinical Application of Next Generation Sequencing to Unexpected Young Onset Dementia: A Pilot Study Richard Caselli
Disclosure:
Dr. Caselli has nothing to disclose.

4:00 PM 082 Gertsmann syndrome and ideomotor apraxia as the first symptoms of a corticobasal syndrome due to a new progranulin mutation Marian Gomez-Beldarrain, MD
Disclosure:
Dr. Gomez-Beldarrain has nothing to disclose.

4:00 PM 083 Metagenomic Analysis of Neural Tissue in patients with Alzheimer’s Disease and Amyotrophic Lateral Sclerosis Kristin Keith
Disclosure:
Dr. Keith has nothing to disclose.

4:00 PM 084 APOE E4 is a lesser risk factor for frontotemporal than amnestic dementia with Alzheimer's neuropathology Letizia G. Borges, MD
Disclosure:
Dr. Borges has nothing to disclose.

4:00 PM 085 Comprehensive phenotypic description of the Belgian GRN founder family and genetic onset age modifiers Sara Van Mossevelde
Disclosure:
Dr. Van Mossevelde has nothing to disclose.

4:00 PM 086 Characterization of the underlying mechanism behind Alzheimer’s disease loci using human genetics Karol Estrada, PhD
Disclosure:
Dr. Estrada has received personal compensation for activities with Biogen Idec as an employee.

4:00 PM 087 Age modulates impact of APOE e4 in Alzheimer’s disease Jaeho Kim
Disclosure:
Dr. Kim has nothing to disclose.

4:00 PM 088 LMNB1-related autosomal dominant leukodystrophy: genetic and clinical studies of three Japanese families Naomi Mezaki
Disclosure:
Dr. Mezaki has nothing to disclose.

4:00 PM 089 Whole Transcriptome Sequencing Reveals Gene Expression Difference and Novel Non-coding RNAs in Alzheimer’s disease Lin Tan
Disclosure:
Dr. Tan has nothing to disclose.

4:00 PM 090 GWAS-Linked Loci and Neuroimaging Measures in Alzheimer’s Disease JieQiong Li
Disclosure:
Dr. Li has nothing to disclose.

4:00 PM 091 The MAPT p.Arg406Trp mutation is a founder mutation in Belgium Sara Van Mossevelde
Disclosure:
Dr. Van Mossevelde has nothing to disclose.

4:00 PM 092 The extended Belgian presenilin 1 Alzheimer family AD/A revisited. Tobi Van den Bossche
Disclosure:
Dr. Van den Bossche has nothing to disclose.

Aging and Dementia: Biomarkers
Start Time Pub. Title Presenter
4:00 PM 093 Elevated cerebrospinal fluid total Tau levels reflects predominant cortical involvement in Alzheimer’s disease Jagan Pillai, MD, PhD
Disclosure:
Dr. Pillai has nothing to disclose.

4:00 PM 095 The BIOCARD Index: A Summary Measure to Predict Onset of Mild Cognitive Impairment Ned Sacktor, MD
Disclosure:
Dr. Sacktor has nothing to disclose.

4:00 PM 096 Expression of Tau and BIN1 in the Skin of Healthy Subjects and Alzheimer's Disease Patients Maria Enriquez Macias
Disclosure:
Dr. Enriquez Macias has nothing to disclose.

4:00 PM 097 Expression profile of Tau protein in oral mucosa of Alzheimer’s disease patients. Luis Arredondo
Disclosure:
Dr. Arredondo has nothing to disclose.

4:00 PM 098 EEG-based geometric modeling and analysis of cognitive deterioration in patients with possible and probable Alzheimer's disease Tal Shnitzer
Disclosure:
Dr. Shnitzer has nothing to disclose.

4:00 PM 099 Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer’s disease Kok Pin Ng, MD
Disclosure:
Dr. Ng has nothing to disclose.

4:00 PM 100 Factors affecting plasma A? levels in IHP Project and second year follow Takumi Nakamura, MD
Disclosure:
Dr. Nakamura has nothing to disclose.

Movement Disorders Poster Discussion Session
Start Time Pub. Title Presenter
4:00 PM 101 Parkinson’s disease, Suicidal ideation and associated risk factors Zahra Rezvani, MD
Disclosure:
Dr. Rezvani has nothing to disclose.

4:00 PM 102 Longitudinal Changes in CSF Biomarkers of Parkinson’s Disease (PD) Patients Seyyed Shayan PourMirbabaei
Disclosure:
Dr. PourMirbabaei has nothing to disclose.

4:00 PM 103 Probabilistic conversion of neurosurgical DBS electrode coordinates into MNI space Andreas Horn
Disclosure:
Dr. Horn has nothing to disclose.

4:00 PM 104 A New Composite Outcome Measure for Parkinson's Disease Ergun Uc, MD
Disclosure:
Dr. Uc has nothing to disclose.

4:00 PM 105 Oculomotor abnormalities are ubiquitous in the spinocerebellar ataxias Christopher Stephen, MB, ChB, MRCP
Disclosure:
Dr. Stephen has nothing to disclose.

4:00 PM 106 Genome-wide Methylation Changes in the Dorsal Motor Nucleus of the Vagus Contribute to the Risk of Parkinson Disease Jeffery Vance, MD, PhD
Disclosure:
Dr. Vance has nothing to disclose.

4:00 PM 107 Phosphorylated alpha synuclein within cutaneous autonomic nerves of patients with Parkinson’s disease (PD) – the implications of sample thickness on results Ningshan Wang, MD, PhD
Disclosure:
Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abide, Acetylon, Astellas, Biogen, Daiichi-Sankyo, Dong-A, Grace, Insys, Lundbeck, Nestle, Novartis, Pfizer, Vertex and Spinifex..

4:00 PM 108 DCTN1-related Neurodegeneration: Perry Syndrome and Beyond Takuya Konno, MD, PhD
Disclosure:
Dr. Konno has nothing to disclose.

4:00 PM 109 A novel paradigm of variable frequency deep brain stimulation to improve freezing of gait in Parkinson’s disease Fumin Jia
Disclosure:
Dr. Jia has nothing to disclose.

4:00 PM 110 Heart rate variability as a screening tool for Parkinson’s disease has age-dependent performance Michael Christiansen
Disclosure:
Dr. Christiansen has nothing to disclose.

Myopathies & Myasthenia Gravis I
Start Time Pub. Title Presenter
4:00 PM 111 RESILIENT: A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients With Sporadic Inclusion Body Myositis Anthony A Amato
Disclosure:
Dr. Amato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge Pharmaceuticals. Dr. Amato has received personal compensation in an editorial capacity for Neurology.

4:00 PM 112 Prolonged Compound Muscle Action Potential Duration and Its Pathological Correlation in Critical Illness Myopathy Bing Liao, MD
Disclosure:
Dr. Liao has nothing to disclose.

4:00 PM 113 Evaluation of Therapeutic Response Between Idiopathic Inflammatory Myopathies and Autoimmune Necrotizing Myopathies at a Tertiary Neuromuscular Center Robert Murphy, MD
Disclosure:
Dr. Murphy has nothing to disclose.

4:00 PM 114 A case of LGMD2A caused by a novel splice site mutation identified by RNA-seq Stefan Nicolau, MD
Disclosure:
Dr. Nicolau has nothing to disclose.

4:00 PM 115 Challenges and Feasibility of an Investigator-Initiated Multi-site Pompe Disease Screening Study Tahseen Mozaffar, MD, FAAN
Disclosure:
Dr. Mozaffar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with aTyr, Alnylam, Alexion, Amicus, Genzyme, Sarepta, MT-Pharma, and Ultragenyx. Dr. Mozaffar has received research support from Alexion, Amicus, aTyr, Genzyme, Grifols, Idera, Ionis Pharmaceuticals, and Ultragenyx.

4:00 PM 116 Childhood activity on progression in limb girdle muscular dystrophy 2I Brianna Brun
Disclosure:
Dr. Brun has nothing to disclose.

4:00 PM 117 The Facioscapulohumeral Dystrophy Composite Outcome Measure: 1 Year Findings Katy Eichinger, PT, DPT, NCS
Disclosure:
Dr. Eichinger has nothing to disclose.

4:00 PM 118 Relative prevalence of limb-girdle muscular dystrophy subtypes at the UC Irvine MDA Clinic Tim Lai, MD
Disclosure:
Dr. Lai has nothing to disclose.

4:00 PM 119 Development and Implementation of Bone Health Protocol (BHP) in Duchenne Muscular Dystrophy (DMD) Alexandra Otto
Disclosure:
Dr. Otto has nothing to disclose.

4:00 PM 120 Long-Term Efficacy of Alglucosidase Alfa in Late-Onset Pompe Disease Paula Clemens
Disclosure:
Dr. Clemens has nothing to disclose.

4:00 PM 121 Perioperative Management of Autoimmune Myasthenia Gravis in Patients Undergoing Thymectomy Francis Huttinger, MD
Disclosure:
Dr. Huttinger has nothing to disclose.

4:00 PM 122 A Pilot Trial of Subcutaneous Immunoglobulin in Patients with Myasthenia Gravis Exacerbation: An Update on Efficacy Grayson Beecher, MD
Disclosure:
Dr. Beecher has nothing to disclose.

4:00 PM 123 Clinical Testing for Titin and Ryanodine Receptor Autoantibodies in Myasthenia Gravis Patients Amy Goldberger, PhD
Disclosure:
Dr. Goldberger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Quest Diagnostics. Dr. Goldberger has received research support from Quest Diagnostics.

4:00 PM 124 Clinical and histopathological findings in myotonic muscular dystrophy type 2 (DM2): retrospective review of 49 DNA-confirmed cases Bhaskar Roy, MD
Disclosure:
Dr. Roy has nothing to disclose.

4:00 PM 125 LRP4 Autoimmune Reactivity in a Diverse Double-Seronegative Myasthenia Gravis Patient Population Keith Morneau
Disclosure:
Dr. Morneau has received personal compensation for activities with Quest Diagnostics as an employee.

4:00 PM 126 Analysis of infections and the relationship to immunosuppressive treatment in autoimmune neuromuscular disorders: a series of 631 patients Devin Prior
Disclosure:
Dr. Prior has nothing to disclose.

4:00 PM 127 Congenital Myesthenic Syndrome with Autophagic Vacuoles Caused by Homozygous c.686-2A>G Mutations in GFPT1 Hacer Durmus, MD
Disclosure:
Dr. Durmus has nothing to disclose.

4:00 PM 128 Retrospective Analysis of the Nephrotoxic and Hemolytic Side Effects of Chronic High Dose IVIG Therapy in Neurologic Disorders Aidan Levine
Disclosure:
Dr. Levine has nothing to disclose.

4:00 PM 129 Utility of Sleep Related questionnaires in Patients with Myasthenia Gravis. Annabel Wang
Disclosure:
Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis. Dr. Wang has received research support from Ionis.

4:00 PM 130 Upper arm, pulmonary and cardiac magnetic resonance imaging for relative disease status in Duchenne muscular dystrophy Ami Mankodi, MD
Disclosure:
Dr. Mankodi has nothing to disclose.

4:00 PM 131 Feasibility and validation of modified oculobulbar facial respiratory score (mOBFRS) in amyotrophic lateral sclerosis (ALS) and sporadic inclusion body myositis (sIBM) Namita Goyal, MD
Disclosure:
Dr. Goyal has nothing to disclose.

4:00 PM 132 A Pilot Trial of Subcutaneous Immunoglobulin in Patients with Myasthenia Gravis Exacerbation: An Update on Safety, Feasibility, and Pharmacokinetics Grayson Beecher, MD
Disclosure:
Dr. Beecher has nothing to disclose.

4:00 PM 133 Congenital Fiber Type Disproportion Myopathy in Children FOUAD ALGHAMDI
Disclosure:
Dr. ALGHAMDI has nothing to disclose.

4:00 PM 134 A Prospective Natural History Study of Sporadic Inclusion Body Myositis: 1-Year Results Namita Goyal, MD
Disclosure:
Dr. Goyal has nothing to disclose.

4:00 PM 135 Evaluation of clinical and electrophysiological myasthenic features in patients with alpha-dystroglycanopathies. Paloma Gonzalez-Perez, MD, PhD
Disclosure:
Dr. Gonzalez-Perez has nothing to disclose.

4:00 PM 136 Five-year experience with dystrophinopathy muscle biopsies Courtney Carlson
Disclosure:
Dr. Carlson has nothing to disclose.

4:00 PM 137 A Retrospective Analysis of Cellcept in Generalized Myasthenia Gravis Anjali Sharma
Disclosure:
Dr. Sharma has nothing to disclose.

4:00 PM 139 Patients derived cellular models to investigate the pathogenesis and to develop therapies for human disorders caused by acid ceramidase deficiency. Dario Ronchi, PhD
Disclosure:
Dr. Ronchi has nothing to disclose.

4:00 PM 140 Molecular Mechanisms of Autoantibodies to Contactin-associated protein-like 2 (Caspr2). Kristina Patterson, MD, PhD
Disclosure:
Dr. Patterson has nothing to disclose.

4:00 PM 141 McArdle Disease: clinical features, muscle biopsy and genetics Paulo Lorenzoni, MD
Disclosure:
Dr. Lorenzoni has nothing to disclose.

4:00 PM 142 A Randomized Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety of IGIV-C in Symptomatic Subjects with Generalized Myasthenia Gravis Rhonda Griffin, RN,BSN
Disclosure:
Ms. Griffin has received personal compensation for activities with Grifols as an employee.

4:00 PM 143 NA NA NA
Disclosure:

4:00 PM 144 NA NA NA
Disclosure:

General Neurology: The Eyes Have It and White Matter Matters
Start Time Pub. Title Presenter
4:00 PM 145 Visual Dysfunction and Retinal Pathology occurs in Stiff-Person Syndrome Alissa Rothman
Disclosure:
Dr. Rothman has nothing to disclose.

4:00 PM 146 Seeing Eye to Eye: A Case of Missed Incidental Optic Nerve Meningioma in the Setting of a Symptomatic Chiari I Malformation Andrea Harriott, MD
Disclosure:
Dr. Harriott has nothing to disclose.

4:00 PM 147 Persistent Upward Gaze in Coma and It's Prognostic Implications Usha Pasupuleti
Disclosure:
Dr. Pasupuleti has nothing to disclose.

4:00 PM 148 Real Eyes Realize Real Lies Mohammad El-Ghanem, MD
Disclosure:
Dr. E-Ghanmh has nothing to disclose.

4:00 PM 149 Three cases of juvenile and adult-onset Niemann-Pick disease type C: Variability in neurological and psychiatrical phenotypes Tomoya Kawazoe
Disclosure:
Dr. Kawazoe has nothing to disclose.

4:00 PM 150 Cerebrotendinous Xanthomatosis Without Neurological Involvement Bianca ML Stelten
Disclosure:
Dr. Stelten has nothing to disclose.

4:00 PM 151 Mechanism of autophagy-lysosomal pathway dysfunction in Gaucher disease iPSC neurons Antanina Voit
Disclosure:
Dr. Voit has nothing to disclose.

4:00 PM 152 An unusual case of Toxic Leukoencephalopathy. Bader Alenzi, MD
Disclosure:
Dr. Alenzi has nothing to disclose.

4:00 PM 153 Tacrolimus Neurotoxicity Mimicking Progressive Multifocal Leukoencephalopathy 16 Years After Renal Transplant Fareed khan
Disclosure:
Dr. Khan has nothing to disclose.

4:00 PM 154 Neuropathic pain as the presenting symptom of adult-onset Alexander’s Disease Jason Massa, DO
Disclosure:
Dr. Massa has nothing to disclose.

4:00 PM 155 A Case of Delayed Post-Hypoxic Leukoencephalopathy Masquerading as a Primary Psychiatric Disorder Dinesh Jillella
Disclosure:
Dr. Jillella has nothing to disclose.

4:00 PM 156 Assessment of radiation-induced white matter changes using myelin water imaging Emmanuelle Lapointe, MD
Disclosure:
Dr. Lapointe has received personal compensation for activities with Roche for serving as a consultant.

4:00 PM 157 Exome sequencing uncovers a rare and treatable condition: Cerebrotendinous Xanthomatosis Ahmet Arac, MD
Disclosure:
Dr. Arac has nothing to disclose.

4:00 PM 158 Nerve Injury Following Sclerotherapy: A Case Report and Review of the Literature Christa Seligman, NP
Disclosure:
Dr. Seligman has nothing to disclose.

4:00 PM 159 Neuropsychological clinical picture of veterans of Afghan war Cholpon Shambetova
Disclosure:
Dr. Shambetova has nothing to disclose.

Neuro-oncology: Gliomas I
Start Time Pub. Title Presenter
4:00 PM 160 IDH mutations define a subset of gliomatosis cerebri patients with improved outcome Ina Ly, MD
Disclosure:
Dr. Ly has nothing to disclose.

4:00 PM 161 A Fifteen-Year Retrospective Series of Patients with Leptomeningeal Spread of Glioma at Memorial Sloan Kettering Cancer Center (MSKCC) Brian Andersen, MD
Disclosure:
Dr. Andersen has nothing to disclose.

4:00 PM 162 Prognostic Importance of Brain Tumor Specific Health-Related Quality of Life Impairments and Fatigue in Newly Diagnosed Glioblastoma Katherine Peters, MD, PhD
Disclosure:
Dr. Peters has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Agios, Novocure, and Abbvie. Dr. Peters has received research support from Biomimetix, Genentech, Merck, VBL Therapeutics, Istari, and Agios.

4:00 PM 163 Defining Molecular Mechanisms of Resistance to Glioblastoma (GBM) Immunity Martha R Neagu, MD
Disclosure:
Dr. Neagu has nothing to disclose.

4:00 PM 164 Intractable seizures and IDH mutation in low grade gliomas Edward Avila, DO
Disclosure:
Dr. Avila has received royalty payments from Up-To-Date.

4:00 PM 165 Early Palliative Care Consultation in Glioblastoma Lauryn Hemminger
Disclosure:
Dr. Hemminger has nothing to disclose.

4:00 PM 166 Compliance of Tumor Treating Fields Therapy and Overall Survival in Glioblastoma Eric Wong, MD
Disclosure:
Dr. Wong has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advance Medical, Merck. Dr. Wong has received research support from Novocure.

4:00 PM 167 Effect of Temozolomide Chemotherapy on Seizure Frequency in Patients with WHO grade II oligodendrogliomas. Aya Haggiagi, MD
Disclosure:
Dr. Haggiagi has nothing to disclose.

4:00 PM 168 Survival Benefit of Glioblastoma Patients after FDA Approval of Temozolomide and Bevacizumab: A Population-Based Study Ping Zhu, PhD
Disclosure:
Dr. Zhu has nothing to disclose.

4:00 PM 169 Comparative Effectiveness of Electronic and Written Patient-Reported Data Entry in Patients with Neuro-Oncologic Disease Mariya Mohammed
Disclosure:
Dr. Mohammed has nothing to disclose.

4:00 PM 170 PIK3CB Inhibitors Selectively Block the Survival of Glioblastoma Cells Lamvy Le
Disclosure:
Dr. Le has nothing to disclose.

4:00 PM 171 Inpatient Use of Bevacizumab in Neuro-Oncology Patients – Challenges and Practice Akanksha Sharma
Disclosure:
Dr. Sharma has nothing to disclose.

4:00 PM 172 Inflammasome Activation in Glioblastoma Multiforme Erin Balcom
Disclosure:
Dr. Balcom has nothing to disclose.

4:00 PM 173 1H-MRS for the differentiation of glioma recurrence from radiation necrosis Ian Crain
Disclosure:
Dr. Crain has nothing to disclose.

4:00 PM 174 Stroke-like migraine attacks in long term survivors of high grade glioma. Pamela New, MD
Disclosure:
Dr. New has nothing to disclose.

4:00 PM 175 Age as a prognostic factor for treatment outcomes in glioblastoma. Kelly Braun, MD
Disclosure:
Dr. Braun has nothing to disclose.

4:00 PM 176 The phenomenon of long-term survivorship of patients with glioblastoma. The Burdenko Neurosurgery Institute experience. Maria Goldberg
Disclosure:
Dr. Goldberg has nothing to disclose.

4:00 PM 177 Tumor Treating Fields (TTF) with Triple Chemotherapy for Recurrent Glioblastoma Jay-Jiguang Zhu, MD, PhD
Disclosure:
Dr. Zhu has nothing to disclose.

4:00 PM 178 Analysis of Glioblastoma Physical Characteristics in Patients Benefiting from Tumor Treating Fields Therapy Pyay San
Disclosure:
Dr. San has nothing to disclose.

4:00 PM 179 Ventriculomegaly in patients with glioblastoma multiforme (GBM) Caroline Miranda, MD
Disclosure:
Dr. Miranda has nothing to disclose.

Headache: Epidemiology and Disease Characteristics
Start Time Pub. Title Presenter
4:00 PM 180 Direct Costs Associated with Migraine in the US Machaon Bonafede
Disclosure:
Dr. Bonafede has received personal compensation for activities with Truven Health Analytics as an employee.

4:00 PM 181 Clinical Characteristics and Treatment Patterns among Patients with Diagnostic Codes for Cluster Headache in U.S. Healthcare Claims Data Casey K. Choong
Disclosure:
Dr. Choong has received research support for activities with Eli Lilly and Company as an employee. Dr. Choong holds stock and/or stock options in Eli Lilly and Company.

4:00 PM 182 Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies in New York State Mia Minen, MD
Disclosure:
Dr. Minen has nothing to disclose.

4:00 PM 183 Migraine with Aura (MA) is the most common phenotype for Post-Traumatic Headache (PTH) James Couch, MD, PhD, FAAN
Disclosure:
Dr. Couch has received personal compensation in an editorial capacity for Springer.

4:00 PM 184 Childhood sexual abuse and migraine among female university students Juliana Gomez
Disclosure:
Dr. Gomez has nothing to disclose.

4:00 PM 185 Natural Course of Cluster Headache: a retrospective cohort study with long-term follow-up Mi Ji Lee
Disclosure:
Dr. Lee has nothing to disclose.

4:00 PM 186 What kind of treatment do patients really want for headache? Natalia Murinova, MD
Disclosure:
Dr. Murinova has nothing to disclose.

4:00 PM 187 A Surveillance of Quality of Care Utilizing the 2014 American Academy of Neurology Quality Measurement Set for Patients with Migraine Jason Lin
Disclosure:
Dr. Lin has nothing to disclose.

4:00 PM 188 Incidence and impact of headaches in the post-traumatic stress disorder Laurent Guilloton, PhD
Disclosure:
Dr. Guilloton has nothing to disclose.

4:00 PM 189 Pseudotumorcerebri in systemic lupus erythematous activity Helena Yacoub
Disclosure:
Dr. Yacoub has nothing to disclose.

4:00 PM 191 An atypical presentation of Tolosa-Hunt syndrome Paula Pire Garcia
Disclosure:

4:00 PM 192 Visual Field Deficits in Patients with Headache Disorders: A 2-year Prospective Cohort Study Fred Odago
Disclosure:
Dr. Odago has nothing to disclose.

4:00 PM 193 Thunderclap headache with no neurological deficit: Clinical differences between Primary and Secondary Causes Patricio Millar Vernetti
Disclosure:
Dr. Millar Vernetti has nothing to disclose.

4:00 PM 194 Headache Update 1917 Noah Rosen, MD
Disclosure:
Dr. Rosen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Eli Lilly, Teva, Supernus, Avanir.

4:00 PM 195 Predictors of healthcare costs among patients with migraine in a commercial claims database Machaon Bonafede
Disclosure:
Dr. Bonafede has received personal compensation for activities with Truven Health Analytics as an employee.

4:00 PM 196 Ergotamine use and overuse in Taiwan : a retrospective cohort study Chuling Chen
Disclosure:
Dr. Chen has nothing to disclose.

4:00 PM 197 The Anxious Brain in Pain: Increased Levels of Anxiety, Depression and Stress Associated with Chronic Daily Headache Patients Presenting to University-based Headache Clinic Natalia Murinova, MD
Disclosure:
Dr. Murinova has nothing to disclose.

4:00 PM 198 Challenges in managing migraine after bariatric surgery Yulia Orlova, MD,PhD
Disclosure:
Dr. Orlova has nothing to disclose.

4:00 PM 199 Alphaherpesviruses and headache disorders: retrospective study Laura J Weinkle
Disclosure:
Dr. Weinkle has nothing to disclose.

4:00 PM 200 Complex Dural Arteriovenous Fistula Masquerading as Pseudotumor Cerebri Lesley Kaye, MD
Disclosure:
Dr. Kaye has nothing to disclose.

4:00 PM 201 Association between Patient and Provider Characteristics and Diagnosis of Migraine: An Observational Electronic Health Record Study Maya Marzouk
Disclosure:
Dr. Marzouk has nothing to disclose.

4:00 PM 202 An Unheard of Diagnosis: Hereditary Syndrome with Migraine and Hearing Loss Andrea Harriott, MD
Disclosure:
Dr. Harriott has nothing to disclose.

4:00 PM 203 A Brief Survey on Academic Headache Centers Knowledge of and Interest in ACGME recognition of Headache Medicine Fellowships Noah Rosen, MD
Disclosure:
Dr. Rosen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Eli Lilly, Teva, Supernus, Avanir.

4:00 PM 204 Inhaled oxygen in cluster headache: Results of the Clusterbusters Medication Use Survey Emmanuelle Schindler, MD, PhD
Disclosure:
Dr. Schindler has nothing to disclose.

4:00 PM 205 Patients Preferences for Headache Treatment Dimos Dimitrios Mitsikostas, MD, PhD
Disclosure:
Dr. Mitsikostas has nothing to disclose.

4:00 PM 206 A Rare Case of Seasonal Episodic Paroxysmal Hemicrania Subhendu Rath, MBBS
Disclosure:
Dr. Rath has nothing to disclose.

4:00 PM 207 Are headaches more common among epilepsy patients with neurocysticercosis compared to other structural brain lesions? Bhavesh Trikamji
Disclosure:
Dr. Trikamji has nothing to disclose.

4:00 PM 208 Uncommon Presentation of an Uncommon Disease: Ophthalmoplegic Migraine with Alternating Contralateral Extraocular Movement Paresis Diego Condes
Disclosure:
Dr. Condes has nothing to disclose.

Pain and Palliative Care
Start Time Pub. Title Presenter
4:00 PM 209 Increase in Rate of Utilization of Withdrawal of Care in Acute Ischemic Stroke in USA Malik Adil, MBBS
Disclosure:
Dr. Adil has nothing to disclose.

4:00 PM 210 Single-nucleotide polymorphism in COL11A2 associated with thermal hyperalgesia in knee osteoarthritis Kwo Wei Ho, MD
Disclosure:
Dr. Ho has nothing to disclose.

4:00 PM 211 Early Palliative Care Consultation Decreases Length of Stay in Severe Stroke Patients Evan R Schloss, MD
Disclosure:
Dr. Schloss has nothing to disclose.

4:00 PM 212 Depression among Inpatients with Low Back Pain: Patient Characteristics and Outcomes Emily Lane Schlitz Fortenberry, MD
Disclosure:
Dr. Schlitz Fortenberry has nothing to disclose.

4:00 PM 213 The Role of Pain-related Fear and Pain Catastrophizing during Acute Spinal Cord Injury Emily Lane Schlitz Fortenberry, MD
Disclosure:
Dr. Schlitz Fortenberry has nothing to disclose.

4:00 PM 214 Neuropalliative Care in Peru: Barriers to Transparency in Communication Anastasia Vishnevetsky
Disclosure:
Dr. Vishnevetsky has nothing to disclose.

4:00 PM 215 Neurological Complication Rates Associated with Epidural Injections Byungkwan Hwang
Disclosure:
Dr. Hwang has nothing to disclose.

4:00 PM 216 Dysfunction of the descending pain modulatory system in neuropathic limb pain related to MS. A case: control clinical and neuroimaging study. Peter Foley
Disclosure:
Dr. Foley has nothing to disclose.

4:00 PM 217 Analysis of risk for side effects due to drug-drug and drug-gene interactions in a cohort of patients with Complex Regional Pain Syndrome Sameer Jain
Disclosure:
Dr. Jain has nothing to disclose.

4:00 PM 218 Primary Care and Palliative Care Needs of ALS Patients in the last 6 months of life Ezgi Tiryaki, MD
Disclosure:
Dr. Tiryaki has nothing to disclose.

4:00 PM 221 Interim Analysis of Practice Changes Following Participation in Online and Live ER/LA Opioid CME/CE Programs from the CO*RE Collaborative Piyali Chatterjee
Disclosure:
Dr. Chatterjee has nothing to disclose.

4:00 PM 222 Do patients with thalamic pain have a specific somatosensory phenotype? Athina Papadopoulou, MD
Disclosure:
Dr. Papadopoulou has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Basic Science
Start Time Pub. Title Presenter
4:00 PM 223 Uniform direct current stimulation induces region-specific long-term modulation of cortical excitability in mouse and human cortex in vitro Yan Sun, PhD
Disclosure:
Dr. Sun has nothing to disclose.

4:00 PM 224 Cannabidiol does not convert to ?9- tetrahydrocannabinol in an in vivo animal model Louise Wray
Disclosure:
Dr. Wray has nothing to disclose.

4:00 PM 225 Positive Allosteric Modulation of Metabotropic Glutamate Receptor 5 (mGluR5) Delays Seizure Onset in a Mouse Model of Viral-induced Seizures Tyler Hanak
Disclosure:
Dr. Hanak has nothing to disclose.

4:00 PM 226 Immune Cell Infiltration in CASPR2-Antibody Associated Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis Erdem Tuzun
Disclosure:
Dr. Tuzun has nothing to disclose.

4:00 PM 227 Type IIA procollagen regulates TGF-? superfamily signaling in epileptogenesis Yuan Gao
Disclosure:
Dr. Gao has nothing to disclose.

4:00 PM 228 The Effect of Cannabidiol on Human CNS-Expressed Voltage-Gated Sodium Channels Royston A. Gray
Disclosure:
Dr. Gray has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Gray has received compensation for serving on the Board of Directors of GW Pharmaceuticals.

4:00 PM 229 Late treatment with choline alfoscerate increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment Jinhyuk Yoo
Disclosure:
Dr. Yoo has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Genetics
Start Time Pub. Title Presenter
4:00 PM 230 Novel Clinical Presentations and Characteristics in Patients with KCNA2 Mutations Monisha Sachdev
Disclosure:
Dr. Sachdev has nothing to disclose.

4:00 PM 231 Phenotype is not Always a Positive Predictor of Detection Rate in Epilepsy Panels Heather Newman
Disclosure:
Dr. Newman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ambry Genetics.

4:00 PM 232 Genetic generalized epilepsy and intellectual disability is associated with 8q21-q22 duplication Arezoo Rezazadeh
Disclosure:
Dr. Rezazadeh has nothing to disclose.

4:00 PM 233 Prevalence of copy number variation in adults with epilepsy and intellectual disability Felippe Borlot, MD
Disclosure:
Dr. Borlot has nothing to disclose.

4:00 PM 234 Many testing roads can lead to KCNQ2 diagnosis. Amal Yussuf
Disclosure:
Dr. Yussuf has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ambry Genetics.

4:00 PM 235 A Novel KCNQ2 Mutation in a Child with Benign Familial Neonatal Seizures Leena Youssefian, MD
Disclosure:
Dr. Youssefian has nothing to disclose.

4:00 PM 236 Increased Epilepsy Prevalence in Adults with 22q11 Deletion Syndrome Robert Wither
Disclosure:
Dr. Wither has nothing to disclose.

4:00 PM 237 Epilepsy phenotype in patients with autism, developmental delay and congenital abnormalities associated to 15q11.2, 15q13.3 and 16p13.11 microdeletions Fabio Nascimento, MD
Disclosure:
Dr. Nascimento has nothing to disclose.

4:00 PM 238 Single center analysis of the yield of genetic testing in suspected genetic etiologies of epilepsy Sarah Barnard
Disclosure:
Dr. Barnard has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Clinical Epilepsy I
Start Time Pub. Title Presenter
4:00 PM 239 Variations in the natural history of epilepsy and epilepsy subgroups Sharon Chiang
Disclosure:
Dr. Chiang has nothing to disclose.

4:00 PM 240 Quantitative EEG in Lennox-Gaustaut Syndrome with Response to Vagal Nerve Stimulator Jalyoung Joe, MD
Disclosure:
Dr. Joe has nothing to disclose.

4:00 PM 241 Incidence of acute symptomatic seizures due to NCC in children accessing government primary schools in south India: Is there a need to sub-categorize acute symptomatic seizures due to CNS infections into those with enduring predisposition for seizure recurrence and those without? Jagarlapudi Murthy, MD, FAAN
Disclosure:
Dr. Murthy has nothing to disclose.

4:00 PM 242 Prevalence of epilepsy and non-epileptic seizures in adults with developmental delay Stephan Schuele, MD, FAAN
Disclosure:
Dr. Schuele has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion, UCB and Eisai.

4:00 PM 243 The value of observing paroxysmal events: Comparing the diagnostic accuracy and confidence for clinical history compared to observation. Brian Hanrahan, MD
Disclosure:
Dr. Hanrahan has nothing to disclose.

4:00 PM 244 Unique Place of Ambulatory EEG (aEEG) in Management of Epilepsy Hardik Doshi, MD
Disclosure:
Dr. Doshi has nothing to disclose.

4:00 PM 245 The predictability of smartphone video in distinguishing epileptic and nonepileptic seizures Sikawat Thanaviratananich, MD
Disclosure:
Dr. Thanaviratananich has nothing to disclose.

4:00 PM 246 Ontogeny of Seizure Semiology: a longitudinal study Ahmed Abdelkader, MD
Disclosure:
Dr. Abdelkader has nothing to disclose.

4:00 PM 247 Catching and counting seizures for patients with epilepsy using an automated telemedicine platform - EpxEpilepsy Stephanie Zhang
Disclosure:
Ms. Zhang has nothing to disclose.

4:00 PM 248 Correlation of Seizure Frequency and Medication Down-titration Rate During Video-EEG Monitoring Sami Al Kasab
Disclosure:
Dr. Alkasab has nothing to disclose.

4:00 PM 249 Use of the DISCOVER form (a structured diagnostic interview) to ensure correct classification in a study of disease impact Jay Louik
Disclosure:
Dr. Louik has nothing to disclose.

Cerebrovascular Disease: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research
Start Time Pub. Title Presenter
4:00 PM 251 Misdiagnosis of CADASIL: A single Medical Center experience Jorge Ortiz-Garcia, MD
Disclosure:
Dr. Ortiz-Garcia has nothing to disclose.

4:00 PM 252 Is Fabry's Disease a Risk Factor for Stroke in Young Patients? Carolina Ikuta
Disclosure:
Dr. Ikuta has nothing to disclose.

4:00 PM 253 A rare cause of stroke in young: PHACE syndrome Keely Fitzgerald, DO
Disclosure:
Dr. Fitzgerald has nothing to disclose.

4:00 PM 254 Deficiency of Adenosine Deaminase 2: A Recently Described Autoinflammatory Disease with Neurological Manifestations Aaron Noll
Disclosure:
Dr. Noll has nothing to disclose.

4:00 PM 255 MELAS Syndrome: How Stroke-like are the Stroke episodes? Nicholas Liaw
Disclosure:
Dr. Liaw has nothing to disclose.

4:00 PM 256 The Single Nucleotide Polymorphisms (SNPs) in Cytochrome P450 2C19 amd Clopidogrel Resistance in Indian Population Arun Shivaraman M M
Disclosure:
Dr. Shivaraman M M has nothing to disclose.

4:00 PM 257 Circulating Microparticles are Associated with Visuospatial Ability in the Framingham Heart Study Hugo Javier Aparicio, MD
Disclosure:
Dr. Aparicio has nothing to disclose.

4:00 PM 258 D-Lactate and Intestinal Fatty-Acid Binding Protein are elevated in serum in patients with acute ischemic stroke Carlos Camara-Lemarroy
Disclosure:
Dr. Camara-Lemarroy has nothing to disclose.

4:00 PM 259 Relationship Between Admission Serum Bilirubin and Severity of Acute Ischaemic Stroke in a Nigerian Tertiary Hospital Babatunde Ademiluyi, MD
Disclosure:
Dr. Ademiluyi has nothing to disclose.

4:00 PM 260 Interleukin-37 is Elevated in Acute Ischemic Stroke. Saif Bushnaq, MD
Disclosure:
Dr. Bushnaq has nothing to disclose.

4:00 PM 261 Increased Cysteinylated Albumin is Associated with More Favorable Outcomes in Ischemic Stroke Patients, A Reflection of Collateral Circulation? Russell Bartt, MD, FAAN
Disclosure:
Dr. Bartt has nothing to disclose.

4:00 PM 262 The relationship between chemerin levels and carotid intima-media thickness in patients with ischemic stroke Caner Demir
Disclosure:
Dr. Demir has nothing to disclose.

4:00 PM 263 Purinoreceptors and VZV Vasculopathy Ann Wyborny
Disclosure:
Dr. Wyborny has nothing to disclose.

4:00 PM 264 Preconditioned M2 microglia by oxygen-glucose deprivation promote functional recovery in ischemic rats Masato Kanazawa, MD
Disclosure:
Dr. Kanazawa has nothing to disclose.

4:00 PM 265 Orosomucoid-1 Protein Dynamics Following Ischemic Stroke in Humans and Mice Hetal Mistry
Disclosure:
Dr. Mistry has nothing to disclose.

4:00 PM 266 Diffusion Tensor Imaging of Corticospinal Tract Recovery after Intra-arterial Mesenchymal Stem Cell Infusion in a Canine Stroke Model Luis Guada, MD
Disclosure:
Dr. Guada has nothing to disclose.

4:00 PM 267 Development and Feasibility of a Canine Endovascular Reversible Middle Cerebral Artery Occlusion Stroke Model: a Novel anterior circulation approach Luis Guada, MD
Disclosure:
Dr. Guada has nothing to disclose.

Cerebrovascular Disease: Pre-Hospital Stroke, Tele-Stroke, and mHealth
Start Time Pub. Title Presenter
4:00 PM 268 Analysis of Run Sheets of EMS Serving a Metropolitan Comprehensive Stroke Center Haitham Hussein, MD
Disclosure:
Dr. Hussein has nothing to disclose.

4:00 PM 269 Early Experience on Intravenous Tissue Plasminogen Activator Delivery in Mobile Stroke Unit Patients with Stroke Mimics Lila Sheikhi, MD
Disclosure:
Dr. Sheikhi has nothing to disclose.

4:00 PM 270 Patient characteristics affecting stroke recognition by emergency medical service providers in Kings County Hospital Center Fernando Cuascut Lassus, MD
Disclosure:
Dr. Cuascut Lassus has nothing to disclose.

4:00 PM 271 Walk-in Versus EMS-prenotified Stroke Codes - Time Targets in a Comprehensive Stroke Center Gurmeen Kaur, MBBS
Disclosure:
Dr. Kaur has nothing to disclose.

4:00 PM 272 Evaluation of NIHSS-Onset to Groin Time (OGT) and Prehospital Acute Stroke Severity Scale (PASS)-OGT scores in prediction of outcomes after Endovascular Treatment in Acute Ischemic Stroke patients: A Retrospective Single-Center Study Muhammad Niazi, MD
Disclosure:
Dr. Niazi has nothing to disclose.

4:00 PM 273 Differences in the last known well time between neurology, ED providers and EMS providers. Alexander Doyle, MD
Disclosure:
Dr. Doyle has nothing to disclose.

4:00 PM 274 Evaluation and Validation of Prehospital Acute Stroke Scale to Predict Large Vessel Occlusion in Patients with Proven Large Vessel Occlusion– Single Center study in US Mohammad El-Ghanem, MD
Disclosure:
Dr. E-Ghanmh has nothing to disclose.

4:00 PM 275 Lytic therapy and mechanical thrombecomty over tele-stroke, a comprehensive stroke center experience Sami Al Kasab
Disclosure:
Dr. Alkasab has nothing to disclose.

4:00 PM 276 Safety and Efficacy of Thrombolysis in Telestroke for the Extended Time Window Alexis Steinberg, MD
Disclosure:
Dr. Steinberg has nothing to disclose.

4:00 PM 277 Door to Page Time to Initiate a Telemedicine Consult Varies Among Spoke Hospitals for Acute Stroke Jaskaren Randhawa, MD, MBBS
Disclosure:
Dr. Randhawa has nothing to disclose.

4:00 PM 278 The Experience of Spoke Hospitals in an Academic Telestroke Network Rajan Gadhia, MD
Disclosure:
Dr. Gadhia has nothing to disclose.

4:00 PM 279 Implementing a Publically Funded Regional Telestroke Network Annemarei Ranta, MD
Disclosure:
Dr. Ranta has nothing to disclose.

4:00 PM 280 Quality Improvement in Telestroke Interactions Deena Nasr, MD
Disclosure:
Dr. Nasr has nothing to disclose.

Cerebrovascular Disease Case Reports I
Start Time Pub. Title Presenter
4:00 PM 281 Apixaban for the treatment of Cerebral Venous Thrombosis: A Report of Two Cases Shishir Rao, MD
Disclosure:
Dr. Rao has nothing to disclose.

4:00 PM 282 Hyperacute Carotid Stenting for Acute Ischemic Stroke After Systemic Thrombolysis with IV rt-PA Erika Marulanda-Londoño
Disclosure:
Dr. Marulanda-Londono has nothing to disclose.

4:00 PM 283 Paradoxical Embolism in the Setting of Inferior Vena Cava Filter Removal Micah Yost, DO
Disclosure:
Dr. Yost has nothing to disclose.

4:00 PM 284 Successful endovascular stroke therapy in a 103-year-old woman Uzoma Duru
Disclosure:
Dr. Duru has nothing to disclose.

4:00 PM 285 4-year-old boy with acute ischemic stroke treated with intravenous tissue plasminogen activase. Talal Derani, MD
Disclosure:
Dr. Derani has nothing to disclose.

4:00 PM 286 Aortic Valvular Papillary Fibroelastoma Leading to Acute Ischemic Stroke in a Pediatric Patient Imran Farooqui, MD
Disclosure:
Dr. Farooqui has nothing to disclose.

4:00 PM 287 Subcortical Aphasias- Questioning Validity of Aphasia as a Cortical Infarct Sign Gurmeen Kaur, MBBS
Disclosure:
Dr. Kaur has nothing to disclose.

4:00 PM 288 Convexal Subarachnoid Hemorrhage and Superficial Siderosis: Under-Recognized Presentations of Cerebral Amyloid Angiopathy Christopher Whiting, DO
Disclosure:
Dr. Whiting has nothing to disclose.

4:00 PM 289 Convexity SAH and multiple punctate infarcts secondary to Cerebral Amyloid Angiopathy Yogesh Gujrati, MD
Disclosure:
Dr. Gujrati has nothing to disclose.

4:00 PM 290 Cerebral Amyloid Angitpathy-Related Inflammation and the changing role of micro bleeds in diagnosis: A Case Report Danielle Lux
Disclosure:
Dr. Lux has nothing to disclose.

4:00 PM 291 "What Are the Odds?": A Rare Clinical Syndrome from a Rare Vascular Condition Caused By a Commonly Used Medication Tarun Girotra
Disclosure:
Dr. Girotra has nothing to disclose.

4:00 PM 292 Bilateral hypertrophic olivary degeneration: case report of an exceedingly rare condition developed after pontine infarct Katherine Kudyba Morone
Disclosure:
Dr. Kudyba Morone has nothing to disclose.

4:00 PM 293 Superior Vena Cava Syndrome Causing Recurrent Intracranial Hemorrhage by Venous Congestion Hatim Attar, MD
Disclosure:
Dr. Attar has nothing to disclose.

4:00 PM 294 Basal ganglia and caudate infarction following episodic hemiballism and dystonia secondary to radiotherapy-induced atherosclerosis in a patient with a right parasellar chondrosarcoma Michael Ruff, MD
Disclosure:
Dr. English has nothing to disclose.

4:00 PM 295 Rare Cases of Thrombotic and Embolic Stroke with Hypereosinophilia Deana Finelli, MD
Disclosure:
Dr. Finelli has nothing to disclose.

4:00 PM 296 Recurrent ischemic strokes as the initial presentation of thrombotic thrombocytopenic purpura with normal platelets: a case report. Lindsay Horton, MD
Disclosure:
Dr. Horton has nothing to disclose.

4:00 PM 297 Eagle’s Syndrome: Viewing a Rare Disorder from a New Perspective Kavit Shah, MD
Disclosure:
Dr. Shah has nothing to disclose.

4:00 PM 298 Bilateral persistent primitive hypoglossal arteries associated with unilateral symptomatic carotid occlusion Riddhi Patira, MD
Disclosure:
Dr. Patira has nothing to disclose.

4:00 PM 299 Rapidly Progressive Occlusive Intracranial Vasculopathy in Graft-versus-Host-Disease Theodore Bowen, MD
Disclosure:
Dr. Bowen has nothing to disclose.

4:00 PM 300 Unique Cerebrospinal Fluid, Diffusion-weighted Spinal Imaging and Spinal Angiography Findings in a Patient with Heroin Myelopathy Kyle Mahoney
Disclosure:
Dr. Mahoney has nothing to disclose.

4:00 PM 301 Cerebrospinal Fluid Drainage for Acute Spinal Cord Infarction Tamara Strohm, MD
Disclosure:
Dr. Strohm has nothing to disclose.

4:00 PM 302 Multiplanar CT Reconstruction to Aid in Recognition of the MCA “Dot” Sign: The Sagittal String Sign Robert Mannel, MD
Disclosure:
Dr. Mannel has nothing to disclose.

Autoimmunity with Infection, Syphilis, Lyme, Tuberculosis, and other Bacteria
Start Time Pub. Title Presenter
4:00 PM 303 40-year old Pilot with Fevers, Diplopia, Hypertropia, Skew Deviation, and Visual Field Loss due to H. parainfluenza endocarditis Brian Stephens, MD
Disclosure:
Dr. Stephens has nothing to disclose.

4:00 PM 304 Brainstem skew deviation as the presenting symptom of mycoplasma pneumoniae meningoencephalomyelitis David Lin, MD
Disclosure:
Dr. Lin has nothing to disclose.

4:00 PM 305 Mixed Curvularia and Klebsiella brain microabscesses in an immunocompromised patient Rituparna Das, MD
Disclosure:
Dr. Das has nothing to disclose.

4:00 PM 306 Ring Enhancing Brain Lesions in a Patient With Sarcoidosis: A Diagnostic Challenge. Carson Van Sanford, MD
Disclosure:
Dr. Van Sanford has nothing to disclose.

4:00 PM 307 Limbic Encephalitis associated with neurosyphilis Omar Al-Louzi
Disclosure:
Dr. Al-Louzi has nothing to disclose.

4:00 PM 308 Neurosyphilis with unique neuroimaging findings Harmanpreet Tiwana, MD
Disclosure:
Dr. Tiwana has nothing to disclose.

4:00 PM 309 The Resurgence of Neurosyphilis – A South Brazilian case series. Conrado Borges
Disclosure:
Dr. Borges has nothing to disclose.

4:00 PM 310 Lyme Neuroborreliosis - A Portuguese Northern Hospital Experience Vera Espírito Santo
Disclosure:
Dr. Espírito Santo has nothing to disclose.

4:00 PM 311 Cervical Radiculopathy as the Initial Presentation for Lyme neuroborreliosis Anas Hannoun, MBBS
Disclosure:
Dr. Hannoun has nothing to disclose.

4:00 PM 312 A case of CNS Lyme disease presenting with multiple cranial neuropathies and mimicking a B cell lymphoma Christopher Perrone, MD
Disclosure:
Dr. Perrone has nothing to disclose.

4:00 PM 313 Chronic inflammatory demyelinating polyneuropathy in a leprosy patient with type 1 reaction Ligia Andrade
Disclosure:
Dr. Andrade has nothing to disclose.

4:00 PM 314 IL-6 is a marker of neuropathic pain in patients with leprosy Marcia Jardim
Disclosure:
Dr. Jardim has nothing to disclose.

4:00 PM 315 Neural pain in leprosy neuropathy Louise Giesel
Disclosure:
Dr. Giesel has nothing to disclose.

4:00 PM 316 Demyelination as presentation in leprosy neuropathy Izabela Pitta
Disclosure:
Dr. Pitta has nothing to disclose.

4:00 PM 317 Acute onset and rapid progression of tubercular meningitis and ischemic infarcts in an immune competent patient. Erica Utigard, DO
Disclosure:
Dr. Utigard has nothing to disclose.

4:00 PM 318 Idiopathic Spinal Cord Compression in a Patient with Newly Diagnosed Tuberculosis Shruti Agashe
Disclosure:
Dr. Agashe has nothing to disclose.

4:00 PM 319 Disseminated Tuberculosis with Initial Presentation of Focal Myositis Diagnosed by Muscle Biopsy Laura Stein, MD
Disclosure:
Dr. Stein has nothing to disclose.

4:00 PM 320 A Rare Case of Central Nervous System Tuberculosis Presenting as Transient Splenial Lesion: Case Report and Literature Review Jr-Wei Wu, MD
Disclosure:
Dr. Wu has nothing to disclose.

4:00 PM 321 Burden of Cerebrovascular Disease and its association in the clinical characteristics, Incidence and outcomes in the hospitalized patients with Community-Acquired Pneumonia in Louisville, KY Pooja SirDeshpande
Disclosure:
Dr. SirDeshpande has nothing to disclose.

4:00 PM 322 Streptococcus pneumoniae meningitis and intracranial vasculopathy: Clinical correlation with improving transcranial Doppler hemodynamics Mohamad Imran Idris
Disclosure:
Dr. Idris has nothing to disclose.

4:00 PM 323 NNICU acquired VAP: Spectrum, risk factors and antibiotic sensitivity profile Man Mohan Mehndiratta, MD, MBBS, FAAN
Disclosure:
Dr. Mehndiratta has nothing to disclose.

4:00 PM 324 Corynebacterium discitis following lumbar puncture Leana Doherty, MD
Disclosure:
Dr. Doherty has nothing to disclose.

4:00 PM 325 Convulsive spasms, autonomic instability and electroencephalographic changes in an Amish female with clinically diagnosed tetanus Murali Kolikonda, MD
Disclosure:
Dr. Kolikonda has nothing to disclose.

4:00 PM 326 Infections masquerading as dementia: An eight year retrospective study Anuja Patil, MD
Disclosure:
Dr. Patil has nothing to disclose.

4:00 PM 327 External Ventricular Drain Related Infection Characteristics and Outcomes: A Case Series Rui Feng
Disclosure:
Dr. Feng has nothing to disclose.

4:00 PM 328 NA NA NA
Disclosure:

CNS Inflammatory Diseases and Differential Diagnosis I
Start Time Pub. Title Presenter
4:00 PM 329 Proposed revised criteria for the diagnosis of CLIPPERS Guillaume Taieb
Disclosure:
Dr. Taieb has nothing to disclose.

4:00 PM 330 Severe recurrent neuroinflammation associated with cytotoxic T-lymphocyte antigen-4 (CTLA4) haploinsufficiency Matthew Schindler, MD, PhD
Disclosure:
Dr. Schindler has nothing to disclose.

4:00 PM 331 NMDAR Encephalitis Following Post-herpes Encephalitis Marco Zoccarato
Disclosure:
Dr. Zoccarato has nothing to disclose.

4:00 PM 332 Disease course and treatment of neurosarcoidosis in a single center cohort study of 113 cases Muhammad Affan
Disclosure:
Dr. Affan has nothing to disclose.

4:00 PM 333 Novel findings in autoimmune encephalitis with antibodies against the metabotropic glutamate receptor 5 (mGluR5) Marianna Spatola
Disclosure:
Dr. Spatola has nothing to disclose.

4:00 PM 334 Clinical profile and long term outcome of the Japanese patients with NMDAR-encephalitis Keiko Tanaka
Disclosure:
Dr. Tanaka has nothing to disclose.

4:00 PM 335 Infliximab for the treatment of neurosarcoidosis: a multi-institutional case series Michael J. Bradshaw
Disclosure:
Dr. Bradshaw has nothing to disclose.

4:00 PM 336 A case of SLIPPERS (Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids) presenting with isolated cognitive dysfunction. Sam Horng, MD, PhD
Disclosure:
Dr. Horng has nothing to disclose.

4:00 PM 337 Patients with Autoimmune Encephalitis Have Persistent Impairment in Neurocognitive and Adaptive Function Anusha Yeshokumar, MD
Disclosure:
Dr. Yeshokumar has nothing to disclose.

4:00 PM 338 Unusual case of a young man with multifocal encephalitis in the context of remote treatment with azathioprine and infliximab for ulcerative colitis – clinical, MRI, neuropathology findings, and exquisite steroid-responsive course David Lin, MD
Disclosure:
Dr. Lin has nothing to disclose.

4:00 PM 339 Patients With Anti-NMDA Receptor Encephalitis have Better Long-Term Functional Outcomes Than Those With Other Autoimmune Encephalitides. Eliza Gordon-Lipkin, MD
Disclosure:
Dr. Gordon-Lipkin has nothing to disclose.

4:00 PM 340 Predictive Variables of Cognitive Dysfunction in Patients with Lupus Helena Alessi
Disclosure:
Dr. Alessi has nothing to disclose.

4:00 PM 341 Immunosuppressive-responsive, chronic, isolated pinealitis Matthew Techy
Disclosure:
Dr. Techy has nothing to disclose.

Pediatric Multiple Sclerosis
Start Time Pub. Title Presenter
4:00 PM 342 Evidence Supporting the Use of MRI as a Surrogate for Clinical Endpoints in Randomized Controlled Trials for Pediatric Multiple Sclerosis Robert Brown
Disclosure:
Dr. Brown has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen IDEC, NeuroRX.

4:00 PM 343 Regional Grey Matter Atrophy in Pediatric Patients with Multiple Sclerosis: A Longitudinal MRI Study Ermelinda De Meo
Disclosure:
Dr. De Meo has nothing to disclose.

4:00 PM 344 Predictors of Long term disability in Pediatric patients with relapse-onset Multiple Sclerosis (MS) on immunomodulatory therapy Areeba Basit, MBBS
Disclosure:
Dr. Basit has nothing to disclose.

4:00 PM 345 Diagnostic algorithm for relapsing acquired demyelinating syndromes of the central nervous system in children Yael Hacohen
Disclosure:
Dr. Hacohen has nothing to disclose.

4:00 PM 346 Final results from the BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS Jutta Gärtner
Disclosure:
Dr. Gaertner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received honoraria for lectures and consultancy fees from Bayer Vital, Biogen, Teva and Novartis..

4:00 PM 347 Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-?-1a Tanuja Chitnis, MD
Disclosure:
Dr. Chitnis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Novartis, Sanofi-Genzyme, and Roche-Genentech.

4:00 PM 348 Early childhood development up to kindergarten age after glatiramer acetate exposure during early pregnancy in women with multiple sclerosis Evelyn Adamus
Disclosure:
Dr. Adamus has nothing to disclose.

4:00 PM 349 Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis Carolyn Schwarz
Disclosure:
Dr. Schwarz has nothing to disclose.

4:00 PM 350 Gender effects on disease progression in pediatric MS population Anat Achiron, MD, PhD
Disclosure:
Dr. Achiron has nothing to disclose.

4:00 PM 351 Childhood Adversity Predicts Clinical Disease Features in Patients with Multiple Sclerosis Natalie Pawlak
Disclosure:
Dr. Pawlak has nothing to disclose.

4:00 PM 352 Natalizumab treatment for highly active pediatric multiple sclerosis Anat Achiron, MD, PhD
Disclosure:
Dr. Achiron has nothing to disclose.

4:00 PM 353 Utility of Physical Disability Outcome Measures in Pediatric-Onset Multiple Sclerosis J. Nicholas Brenton, MD
Disclosure:
Dr. Brenton has nothing to disclose.

4:00 PM 354 Early ganglion cell layer loss is seen in pediatric optic neuritis Colin Wilbur, MD
Disclosure:
Dr. Wilbur has nothing to disclose.

4:00 PM 355 Factors associated with Pediatric Onset Multiple Sclerosis slowed gait, does mood matter? Carolyn Bauer
Disclosure:
Dr. Bauer has nothing to disclose.

4:00 PM 356 Symbol Digit Modalities Test and Academic Outcomes in Pediatric MS: Preliminary Findings Wendy Vargas, MD
Disclosure:
Dr. Vargas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion Pharmaceuticals. Dr. Vargas has received research support from Teva Pharmaceuticals.

4:00 PM 357 Fine motor speed predicts cognitive functioning in pediatric onset multiple sclerosis (POMS) David Liu
Disclosure:
Dr. Liu has nothing to disclose.

Pregnancy and Multiple Sclerosis
Start Time Pub. Title Presenter
4:00 PM 358 Multiple Sclerosis and Pregnancy: Moving Towards a Better Understanding of Treatment Practices by Neurologists for Women with Multiple Sclerosis of Childbearing Age Lori Travis
Disclosure:
Dr. Travis has received personal compensation for activities with Teva, Biogen, Novrtis, Genzyme for participating in the speakers bureau. Dr. Travis has received research support from Teva.

4:00 PM 359 Pregnancy Outcome and Teriflunomide Treatment Exposure for Relapsing Remitting Multiple Sclerosis A 4 year follow up Clementine Karageorgiou, MD
Disclosure:
Dr. Karageorgiou has nothing to disclose.

4:00 PM 360 Pregnancy outcomes with interferons or glatiramer acetate exposure in Multiple Sclerosis Nigar Dargah-zada, MD
Disclosure:
Dr. Dargah-Zada has nothing to disclose.

4:00 PM 361 Multiple Sclerosis Relapse Rates, Before, During, and After Pregnancy: a US Retrospective Claims Database Analysis Amy L. Phillips, PharmD
Disclosure:
Dr. Phillips has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of EMD Serono, Inc., Rockland, MA, USA (a business of Merck KGaA, Darmstadt, Germany).

4:00 PM 362 Outcomes following natalizumab exposure throughout pregnancy in patients with relapsing multiple sclerosis (RMS) or Crohn’s disease Susan Friend
Disclosure:
Dr. Friend has received personal compensation for activities with Biogen as an employee. Dr. Friend has hold stock and/or stock options in Biogen.

4:00 PM 363 Unintended pregnancies occurring during clinical trials for multiple sclerosis therapeutics Afsaneh Shirani, MD
Disclosure:
Dr. Shirani has nothing to disclose.

4:00 PM 364 Quantitative MRI analysis of cerebral lesions and atrophy in post-partum multiple sclerosis patients Fariha Khalid, MD
Disclosure:
Dr. Khalid has nothing to disclose.

4:00 PM 365 Pregnancy Outcomes in Patients with MS Exposed to Branded Glatiramer Acetate Peleg Baruch
Disclosure:
Dr. Baruch has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva.

4:00 PM 366 Rate of relapse occurrence in pregnancy and post-partum period Raed Alroughani, MD, FAAN
Disclosure:
Dr. Alroughani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme. Dr. Alroughani has received research support from Biogen, Novartis, Sanofi-Genzyme.

4:00 PM 367 Disease activity during pregnancy and pregnancy outcomes in patients with multiple sclerosis treated with Alemtuzumab – A case series from the German MS and Pregnancy Registry Kerstin Hellwig
Disclosure:
Dr. Hellwig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speaker honoraria: Biogen Idec, Teva, Sanofi Aventis, Novartis, Bayer Healthcare, Merck Serono.

Tools and Measures for Clinical Evaluation in Multiple Sclerosis
Start Time Pub. Title Presenter
4:00 PM 368 Multiple Sclerosis Care Optimization Tool (MS-COT): A Clinical application prototype to predict future disease activity Diego Silva
Disclosure:
Dr. Silva has nothing to disclose.

4:00 PM 369 Multicenter MRI standardization to allow quantitative metrics in routine care of multiple sclerosis patients: the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) initiative Robert Bermel, MD
Disclosure:
Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, and Novartis. Dr. Bermel has received research support from Biogen and Genentech.

4:00 PM 370 The Expanded Timed Up-and-Go (ETUG) is significantly and strongly correlated with EDSS in multiple sclerosis patients Caila Vaughn
Disclosure:
Dr. Vaughn has nothing to disclose.

4:00 PM 371 Brain Age: A novel approach to quantify the impact of multiple sclerosis on the brain Joel Raffel
Disclosure:
Dr. Raffel has received personal compensation for activities with GE Healthcare.

4:00 PM 372 Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS): Initial Launch Experience Robert Bermel, MD
Disclosure:
Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, and Novartis. Dr. Bermel has received research support from Biogen and Genentech.

4:00 PM 373 New multiple sclerosis severity model predicts future accumulation of disability Bibiana Bielekova, MD, FAAN
Disclosure:
Dr. Bielekova has nothing to disclose.

4:00 PM 374 Development of a Gait Module to Complement the 12-item Patient-Reported Multiple Sclerosis Walking Scale Shih-Yin Chen
Disclosure:
Dr. Chen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Biogen. Dr. Chen holds stock and/or stock options in Holds stock/stock options in Biogen.

4:00 PM 375 Effectiveness of a Medical Education Activity on Improving Knowledge of Prognostic Factors in Multiple Sclerosis among Neurologists Thomas Finnegan
Disclosure:
Dr. Finnegan has nothing to disclose.

4:00 PM 376 Continuous Daily Assessment Of Multiple Sclerosis Disability Using Remote Step Count Monitoring Valerie Block
Disclosure:
Dr. Block has nothing to disclose.

4:00 PM 377 Wearable electromyogram device associated with disability outcomes in adults with multiple sclerosis Jennifer Graves, MD, PhD
Disclosure:
Dr. Graves has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Graves has received research support from Biogen and Genentech.

4:00 PM 378 The state of the art of technologies for the assessment of gait in multiple sclerosis: Filling the gap Stephen Czarnuch
Disclosure:
Dr. Czarnuch has nothing to disclose.

4:00 PM 379 Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: Results of a randomized trial E. Ann Yeh, MD
Disclosure:
Dr. Yeh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Juno Therapeutics, Novartis, ACI.. Dr. Yeh has received research support from Teva, unrestricted educational funds for educational symposium.

Biomarkers and Experimental Studies for Multiple Sclerosis I
Start Time Pub. Title Presenter
4:00 PM 380 Death of oligodendrocytes induced by secretory products of B cells of patients with relapsing multiple sclerosis is mediated by extracellular vesicles Robert Lisak, MD, FAAN
Disclosure:
Dr. Lisak has received personal compensation from Teva Neuroscience, Teva Pharmaceuticals, Ltd; Questcor; Acorda, GLG Consultants, Syntimmune, Celgene,RedHill Biopharma, Ltd for CME or consulting. Dr. Lisak has received research support from Teva Pharmaceuticals; Novartis, Ilex; Questcor/Mallincrodt,, Ltd, Biogen/Idec, Genzyme (Sanofi), Genetec (Roche) and Medimmune.

4:00 PM 381 MCAM in Multiple Sclerosis: a biomarker of disease activity? Alexandra Muccilli, MD
Disclosure:
Dr. Muccilli has nothing to disclose.

4:00 PM 382 Baseline characteristics and cytokine profiles across demographic subsets in the Intermountain Multiple Sclerosis Project Laura Baldassari, MD, MHS
Disclosure:
Dr. Baldassari has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva.

4:00 PM 383 Clonal B cell persistence in multiple sclerosis: A longitudinal immune repertoire study Ariele Greenfield, MD
Disclosure:
Dr. Greenfield has nothing to disclose.

4:00 PM 384 Basic Immunological Profile Changes of SPMS Patients Treated with BAF312 Yang Mao-Draayer, MD
Disclosure:
Dr. Mao-Draayer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Bayer Pharmaceutical, Teva, Genzyme, EMD Serono. Dr. Mao-Draayer has received research support from NIH NIAID Autoimmune Center of Excellence: UM1-AI110557; NIH NINDS R01-NS080821; Novartis and Chugai.

4:00 PM 385 Novel CSF biomarkers NFL and CXCL 13,-relationship with other CSF parameters and disease variables in MS Björn Evertsson
Disclosure:
Dr. Evertsson has nothing to disclose.

4:00 PM 386 Construction of a new in vitro blood-brain barrier (BBB) model that incorporates triple-culturing system of BBB components. Yukio Takeshita, MD, PhD
Disclosure:
Dr. Takeshita has nothing to disclose.

4:00 PM 387 Sera of relapsing-remitting multiple sclerosis (RRMS) patients express high levels of bone morphogenetic protein-2 that correlate with BMP-4 and BMP-5 levels, and induce low neuronal phenotype in vitro. moran Penn
Disclosure:
Dr. Penn has nothing to disclose.

4:00 PM 388 Longitudinal monitoring of metabolic alterations in TMEV mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy Michelle Sudyn
Disclosure:
Dr. Sudyn has nothing to disclose.

4:00 PM 389 Serial MRI of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis Suyog Pol
Disclosure:
Dr. Pol has nothing to disclose.

4:00 PM 390 Combinatorial CNS Cell-Specific CSF Biomarkers for Multiple Sclerosis Ruturaj Masvekar
Disclosure:
Dr. Masvekar has nothing to disclose.

4:00 PM 391 Expression and regulation of GMCSF in immune cell subsets in MS Cris S Constantinescu, MD, PhD
Disclosure:
Dr. Constantinescu has nothing to disclose.

4:00 PM 392 Comprehensive analysis of the intrathecal B-cell response in patients with multiple sclerosis [MS] Antara Finney-Stable
Disclosure:
Dr. Finney-Stable has nothing to disclose.

4:00 PM 393 Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in multiple sclerosis Stefanie Hahn
Disclosure:
Dr. Hahn has nothing to disclose.

4:00 PM 394 Interferon-? mediates oligodendrocyte-associated CYP17A1 repression in multiple sclerosis: dehydroepiandrosterone-sulphate regulates inflammatory demyelination Roobina Boghozian
Disclosure:
Dr. Boghozian has nothing to disclose.

4:00 PM 395 Fatty acid-binding protein 4 (FABP4) enhances TLR2, TNFa and IL23 expression in CD14+ monocytes in vitro. Kiandokht Keyhanian
Disclosure:
Dr. Keyhanian has nothing to disclose.

4:00 PM 396 Microglial modulation for gray matter neuroprotection: mixed-lineage kinase 3 inhibitor URMC-099 protects hippocamapal synapses in EAE Matthew Bellizzi, MD
Disclosure:
Dr. Bellizzi has nothing to disclose.

4:00 PM 397 Increased methionine sulfoxide levels in the CSF of multiple sclerosis patients. Zerina Balic
Disclosure:
Dr. Balic has nothing to disclose.

4:00 PM 398 Tumefactive demyelinating lesions (TDLs): Does MOG IgG play a role? Ayse Altintas
Disclosure:
Dr. Altintas has nothing to disclose.

4:00 PM 400 Peripheral CD19+ cell counts and therapy intervals as a surrogate marker for B-cell depleting therapy in multiple sclerosis and neuromyelitis optica Jan Bolz
Disclosure:
Dr. Bolz has received research support from Biogen Idec and Novartis Pharma.

4:00 PM 401 Aberrant profile of serum exosomal miRNA and peripheral blood cells secretion of exosomes in RR MS Marcin Mycko, MD
Disclosure:
Dr. Mycko has nothing to disclose.

4:00 PM 402 Oligodendroglial FGFR 1 gene targeting protects against inflammation and demyelination in EAE through ERK/AKT phosphorylation Ranjithkumar Rajendran
Disclosure:
Dr. Rajendran has nothing to disclose.

4:00 PM 403 Longitudinal Diffusion Tensor Imaging and Quantitative Susceptibility Mapping of encephalomyelitis driven demyelinating rodent brain Suyog Pol
Disclosure:
Dr. Pol has nothing to disclose.

4:00 PM 404 Early hematopoiesis in multiple sclerosis patients. Daniel Jons, MD
Disclosure:
Dr. Jons has nothing to disclose.

4:00 PM 405 SINE Compounds Demonstrate Efficacy in a Preclinical Model of Multiple Sclerosis and an In Vitro Screening of Viral Agents of Coinfection Sharon Tamir
Disclosure:
Dr. Tamir has received personal compensation for activities with Karyopharm Therapeutics Inc., as an employee.

4:00 PM 406 MSDx Complex-1: A potential marker of drug response? Vanessa White
Disclosure:
Dr. White has received personal compensation for activities with MSDx Inc. as an employee.

4:00 PM 407 Anti-GAD65 Antibody Testing at a Tertiary Care Center Ivana Vodopivec, MD
Disclosure:
Dr. Vodopivec has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.

Neuroscience Research Prize Recipients
Start Time Pub. Title Presenter
4:00 PM 408 ALZCan: Predicting Future Onset of Alzheimer's Using Polygenic Risk Scores, Cognitive Tests, CSF Biomarkers, and Multiple Neuroimaging Modalities Pravin Ravishanker
Disclosure:

4:00 PM 409

Inhibiting the Proliferation of Patient-Derived Glioblastoma Multiforme (GBM) Cells and U-87 MG Cell Line Using Leaf Extract of Bacopa monnieri

Tejas Athni
Disclosure:
Dr. Athni has nothing to disclose.

4:00 PM 410 Triggering the brain to heal itself after traumatic brain injury: where glia, anesthesia and nanomedicine meet Gokul Kannan
Disclosure:

Register Now

Related Courses